# Fitlife Brands, Inc.: Form 10-Q for the period ended Sep 30, 2017

- Company: [Fitlife Brands, Inc.](/companies/ftlf.md) (CIK 1374328)
- Form: 10-Q
- Filed: 2017-11-14
- Accepted by EDGAR: Nov 14, 2017, 16:18 ET
- Period: 2017-09-30
- Accession: 0001654954-17-010632
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1374328/000165495417010632/ftlf10q_sep302017.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1374328/000165495417010632/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-07-01 to 2017-09-30 | $4.0m | us-gaap:Revenues |
| Revenue | 9 months, 2017-01-01 to 2017-09-30 | $14.6m | us-gaap:Revenues |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $1.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-01-01 to 2017-09-30 | $4.9m | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | −$483.1k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-01-01 to 2017-09-30 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $28.2k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $83.9k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-07-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-01-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | −$511.4k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-01-01 to 2017-09-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-07-01 to 2017-09-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-01-01 to 2017-09-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-07-01 to 2017-09-30 | 10,537,805 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-01-01 to 2017-09-30 | 10,488,135 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | $247.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2017-01-01 to 2017-09-30 | $20.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-09-30 | $1.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $7.7m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $14.8m | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $5.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-09-30 | $5.5m | us-gaap:Liabilities |
| Long-term debt | at 2017-09-30 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-09-30 | $506.9k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-09-30 | $9.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,852 characters.

### Forward-Looking Statements

Management’s Discussion and Analysis contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included in this Form 10-Q, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company adopted at management’s discretion, the most conservative recognition of revenue based on the most astringent guidelines of the SEC. Management will elect additional changes to revenue recognition to comply with the most conservative SEC recognition on a forward going accrual basis as the model is replicated with other similar markets. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth therein.

Forward-looking statements involve risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors and risks that could affect our results and achievements and cause them to materially differ from those contained in the forward-looking statements include those identified in the section titled “*Risk Factors”* in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as well as other factors that we are currently unable to identify or quantify, but that may exist in the future.

In addition, the foregoing factors may affect generally our business, results of operations and financial position. Forward-looking statements speak only as of the date the statement was made. We do not undertake and specifically decline any obligation to update any forward-looking statements.

### Overview

FitLife Brands, Inc. (the “*Company”*) is a national provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the brand names NDS Nutrition Products™ (“*NDS”) (*www.ndsnutrition.com), PMD™ (www.pmdsports.com), SirenLabs™ (www.sirenlabs.com), CoreActive™ (www.coreactivenutrition.com), and Metis Nutrition™ (www.metisnutrition.com) (together, “*NDS Products”*). With the consummation of the merger with iSatori, Inc. (“*iSatori”*) on September 30, 2015, which became effective on October 1, 2015, described below (the “*Merger”*), the Company added several brands to its product portfolio, including iSatori (www.isatori.com), BioGenetic Laboratories, and Energize (together, “*iSatori Products”).* The NDS Products are distributed principally through franchised General Nutrition Centers, Inc. (“*GNC”*) stores located both domestically and internationally, and, with the addition of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 25,000 retail locations, which include specialty, mass, and online.

The Company was incorporated in the State of Nevada on July 26, 2005. In October 2008, the Company acquired the assets of NDS Nutritional Products, Inc., a Nebraska corporation, and moved those assets into its wholly owned subsidiary NDS Nutrition Products, Inc., a Florida corporation (“*NDS”*). The Company’s NDS Products are sold through NDS and the iSatori Products are sold through iSatori, Inc., a Delaware corporation and a wholly owned subsidiary of the Company.

FitLife Brands is headquartered in Omaha, Nebraska and maintains an office in Golden, Colorado, which it acquired in connection with the Merger. For more information on the Company, please go to http://www.fitlifebrands.com. The Company’s common stock currently trades under the symbol FTLF on the OTC:PINK market.

### Results of Operations

### Comparison of Three and Nine Months Ended September 30, 2017 to the Three and Nine Months Ended September 30, 2016

*Net Sales.* Revenue for the three months ended September 30, 2017 decreased 24.6% to $4,025,580 as compared to $5,340,616 for the three months ended September 30, 2016. Revenue for the nine months ended September 30, 2017 decreased 32.3% to $14,637,273 as compared to $21,615,605 for the nine months ended September 30, 2016. Revenue for the nine months ended September 30, 2017 included a one-time non-recurring adjustment of $700,000 related to a margin support credit memorandum entered into between the Company and GNC in April 2017 as well as certain other elements deemed non-recurring by management.

Revenue attributable to the Company’s NDS Nutrition division for the three months ended September 30, 2017 was $3,215,372 as compared to $4,206,557 for the three months ended September 30, 2016. Revenue attributable to the Company’s NDS Nutrition division for the nine months ended September 30, 2017 was $10,938,272, as compared to $15,463,141 for the nine months ended September 30, 2016. The decrease in total revenue attributable to NDS products in the three month and nine months ended September 30, 2017 compared to the comparable period last year is principally attributable to the impact of convention revenue during the second quarter in 2016 and the Company’s election not to attend the convention in 2017, as well as efforts of the Company’s largest distribution partner to reduce average existing inventory levels to fulfill product demand in the short term, which resulted in an unprecedented divergence of wholesale purchases compared to product movement at retail.

Revenue attributable to the Company’s iSatori operating division for the three months ended September 30, 2017 was $810,208, as compared to $1,134,058 for the three months ended September 30, 2016. Revenue attributable to the Company’s iSatori operating division for the nine months ended September 30, 2017 was $3,699,001, as compared to $6,152,464 for the nine months ended September 30, 2016. The decrease in total revenue attributable to iSatori products in the three and nine months ended September 30, 2017 compared to the comparable periods last year is attributable to several factors, principally to fewer new product introductions during the period as compared to the prior year and the restructuring and reorganization at iSatori’s largest third-party distributor. The impact of both are expected to stabilize in the coming quarters and management anticipates that it will continue to benefit from new product introductions going forward as a key element of its strategic growth plan for both iSatori and NDS.

*Cost of Goods Sold.* Cost of goods sold for the three months ended September 30, 2017 decreased to $2,550,760 as compared to $3,353,224 for the three months ended September 30, 2016. The decrease during the three-month period is principally attributable to lower sales in the period. Cost of goods sold for the nine months ended September 30, 2017 decreased to $9,718,670 as compared to $12,469,081 for the nine months ended September 30, 2016. The decrease during the nine-month period is principally attributable to lower sales in the period. Notwithstanding the decrease, cost of goods sold was negatively impacted during the nine months ended September 30, 2017 by an unusually large amount of inventory write-offs totaling approximately $376,000, of which $276,000 related to the write off of all remaining inventory of product containing picamilion.

*General and Administrative Expense.* General and administrative expense for the three months ended September 30, 2017 decreased to $1,030,215 as compared to $ 1,131,692 for the three months ended September 30, 2016. General and administrative expense for the nine months ended September 30, 2017 decreased to $3,200,218 as compared to $ 3,854,128 for the nine months ended September 30, 2016. The decrease in general and administrative expense for the three and nine months ended September 30, 2017 is s principally attributable to ongoing cost reduction initiatives as well as the continued integration efforts at the iSatori division.

*Selling and Marketing Expense.* Selling and marketing expense for the three months ended September 30, 2017 decreased to $828,829 as compared to $ 1,088,400 for the three months ended September 30, 2016. Selling and marketing expense for the nine months ended September 30, 2017 decreased to $2,689,587 as compared to $ 3,138,323 for the nine months ended September 30, 2016. The decrease in selling and marketing expense for the three and nine and month periods ended September 30, 2017 is principally the result of budgetary controls and efficiencies gained through the acquisition of iSatori.

*Depreciation and Amortization.* Depreciation and amortization for the three months ended September 30, 2017 decreased to $98,917 as compared to $125,751 for the three months ended September 30, 2016. Depreciation and amortization for the nine months ended September 30, 2017 decreased to $335,566 as compared to $376,502 for the nine months ended September 30, 2016.

*Net Income/(Loss).* We generated a net loss of $(511,384) for the three-month period ended September 30, 2017 as compared to a net loss of $(360,718) for the three months ended September 30, 2016. The increase in net loss for the three-month period ended September 30, 2017 compared to the comparable period last year is principally attributable to lower sales volumes due to a variety of factors discussed above. We generated a net loss of $(1,395,833) for the nine-month period ended September 30, 2017 as compared to a net income of $1,532,472 for the nine months ended September 30, 2016, which was principally attributable to a one-time non-recurring adjustment of $700,000 related to a margin support credit memorandum entered into between the Company and GNC in April 2017, lower sales volumes, increased write-off activity and the decision to not participate in 2017 annual franchise convention.

### Liquidity and Capital Resources

At September 30, 2017, we had positive working capital of approximately $2,205,687, compared to positive working capital of approximately $3,482,120 at December 31, 2016. Our principal sources of liquidity at September 30, 2017 consisted of $1,104,872 of cash and $3,380,984 from accounts receivable. The decrease in working capital is principally attributable to our net loss incurred during the quarter ending September 30, 2017.

The Company has historically financed its operations primarily through equity and debt financings, and more recently, cash flow from operations. The Company has also provided for its cash needs by issuing common stock, options and warrants for certain operating costs, including consulting and professional fees. Although the anticipated cash derived from operations and existing cash resources are expected to provide for the Company’s liquidity for the next 12 months, our line of credit with U.S. Bank National Bank Association ("*U.S. Bank*") matures on December 15, 2017, at which time all amounts owed U.S. Bank will be due and payable. The Company has received a notice of default from U.S. Bank relating to its line of credit. The Company is currently negotiating with alternative lenders to replace U.S. Bank, and to satisfy our obligations to U.S. Bank under the line of credit and our term note. In the event the Company is unable to enter into a loan agreement with an alternative lender prior to maturity of the current line of credit with U.S. Bank, or in the event that all amounts due U.S. Bank, totalling approximately $2.4 million, are accelerated as a result of the event of default, the Company’s financial condition will be negatively affected, and such affect will be material.

*Cash Provided by (Used in) Operations.* Our cash provided by operating activities for the nine months ended September 30, 2017 was $247,818, as compared to cash provided by operating activities of $357,665 for the nine months ended September 30, 2016. The decrease is principally attributable to a decrease in revenue during the nine-month period, and variations in certain working capital accounts consistent with normal business practices and outcomes. Net working capital decreased to $2,205,687 as of the quarter ended September 30, 2017 compared to $4,758,923 as of September 30, 2016.

*Cash Used in Investing Activities.* Cash used in investing activities for the nine months ended September 30, 2017 was $(20,305) as compared to $(19,592) used in investing activities for the nine months ended September 30, 2016.

*Cash Provided by (Used in) Financing Activities.* Our cash used in financing activities for the nine months ended September 30, 2017 was $(415,681), as compared to cash provided by financing activities of $115,739 during the nine months ended September 30, 2016. The primary difference was that we drew down $520,000 during the nine months ended September 30, 2016 from our existing line of credit with U.S. Bank and made no draw downs on the line of credit during the nine months ended September 30, 2017. The line of credit matured on June 15, 2017; however, U.S. Bank agreed to extend the maturity date of the line of credit until December 15, 2017. The line of credit is secured by substantially all of the assets of the Company. In connection with an amendment to the line of credit dated August 28, 2017, the Company agreed to additional loan covenants, one of which the Company was in violation of as of September 30, 2017. Although no assurances can be given, we currently intend to replace the line of credit with U.S. Bank with an alternative lender, and therefore pay U.S. Bank all amounts due U.S. Bank, totaling approximately $2.5 million at September 30, 2017, at maturity inclusive of both the revolving line of credit and outstanding term loan (see Item 3).

### Goodwill and Indefinite-Lived Intangible Assets

The Company had goodwill and indefinite-lived intangible assets with a carrying value of $6,212,193 and $6,507,505, respectively, as of the quarter ended September 30, 2017 and December 31, 2016. In accordance with ASC Topic 350 – Goodwill and Other Intangible Assets, in lieu of amortizing such amounts the Company assesses the carrying value of such intangible assets for impairment on a periodic basis and records an impairment charge if the carrying value of such intangible assets exceeds the estimated fair value of the reporting unit, which in this case is the Company. The Company performed its annual goodwill impairment test as of December 31, 2016, which did not indicate the existence of an impairment at that time. While the fiscal year-to-date financial performance has not met our expectations, and the enterprise value of the Company based on current price of the stock the Company may fluctuate at or near the recorded levels of goodwill and indefinite-lived intangible assets, Management does not consider these results to be a triggering event requiring the performance of an interim goodwill impairment test. The Company will continue to monitor its operating results for indicators of impairment and perform additional tests as necessary. The Company's fiscal 2017 annual impairment test will be performed as of December 31, 2017, which could result in an impairment charge to goodwill depending on the Company’s finalized forecast for fiscal 2018 and other market conditions.

### Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. We evaluate, on an on-going basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our consolidated financial statements. The SEC considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation. For a more detailed discussion of the accounting policies of the Company, see Note 3 of the Notes to the Condensed Consolidated Financial Statements, “Summary of Significant Accounting Policies”.

We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our consolidated financial statements.

#### Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“*GAAP”*) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

These estimates and assumptions also affect the reported amounts of revenues, costs and expenses and valuations of long term assets, deferred tax assets and equity instruments issued for services during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

#### Impairment of Long-Lived Assets

The Company had goodwill and intangible assets with a carrying value of $6,212,193 and $6,507,505, respectively, as of September 30, 2017 and December 31, 2016. In accordance with ASC Topic 350 – Goodwill and Other Intangible Assets, the Company assesses the carrying value of such intangible assets for impairment on a periodic basis and records an impairment charge if the carrying value of such intangible assets exceeds the estimated fair value of the reporting unit, which in this case is the Company. The Company performed its annual goodwill impairment test as of December 31, 2016, which did not indicate the existence of an impairment at that time. While the fiscal year-to-date financial performance have not met our expectations, and the enterprise value of the Company based on the current price of our common stock may fluctuate at or near the recorded levels of goodwill and indefinite-lived intangible assets, Management does notconsider these results to be a triggering event requiring the performance of an interim goodwill impairment test. The Company will continue to monitor its operating results for indicators of impairment and perform additional tests as necessary. The Company's fiscal 2017 annual impairment test will be performed as of December 31, 2017, which could result in an impairment charge to goodwill depending on the Company’s finalized forecast for fiscal 2018 and other market conditions.

#### Share Based Payment

The Company issues stock options, warrants and common stock as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation to employees in accordance with FASB ASC718 "Compensation - Stock Compensation." Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the requisite service period.

The Company accounts for share-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 "Equity - Based Payment to Non-Employees." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The final fair value of the share-based payment transaction is determined at the performance completion date. For interim periods, the fair value is estimated and the percentage of completion is applied to that estimate to determine the cumulative expense recorded.

The Company values stock compensation based on the market price on the measurement date. For employees this is the date of grant, and for non-employees, this is the date of performance completion. The Company values stock options and warrants using the Black-Scholes option pricing model.

### Recent Accounting Polices

See Footnote 3 in the accompanying financial statements for a discussion of recent accounting policies.

### WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

## Market risk

As filed, 1,411 characters.

Our business is currently conducted principally in the United States. As a result, our financial results are not affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets. We do not engage in hedging transactions to reduce our exposure to changes in currency exchange rates, although as the geographical scope of our business broadens, we may do so in the future.

Our exposure to risk for changes in interest rates relates primarily to our investments in short-term financial instruments. Investments in both fixed rate and floating rate interest earning instruments carry some interest rate risk. The fair value of fixed rate securities may fall due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income may fall short of expectations due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.

We do not hold any derivative instruments and do not engage in any hedging activities.

## Controls and procedures

As filed, 3,992 characters.

(a) *Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“*COSO”*). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the COSO to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was effective as of September 30, 2017. This Quarterly Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our internal control over financial reporting was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

(b) *Changes in Internal Controls Over Financial Reporting*

There have been no changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended September 30, 2017. There have not been any significant changes in the Company's critical accounting policies identified since the Company filed its Annual Report on Form 10-K as of December 31, 2016.

### PART II

### OTHER INFORMATION

## Risk factors

As filed, 2,045 characters.

Our results of operations and financial condition are subject to numerous risks and uncertainties described in our Annual Report on Form 10-K for our fiscal year ended December 31, 2016, filed on April 17, 2017. You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted. As of September 30, 2017, there have been the following changes to the disclosures made in the above-referenced Form 10-K.

***We have received a notice of default from U.S. Bank relating to our line of credit with U.S. Bank. Although U.S. Bank has elected not to exercise its rights and remedies relating to the default, in the event U.S. Bank declares all amounts due U.S. Bank caused by the default immediately due and payable prior to maturity, or approximately $2.4 million, or we are otherwise unable to replace the line of credit with an alternative lender, our financial condition will be materially and negatively affected.***

The Company is currently in violation of a loan covenant set forth in the Company’s revolving line of credit of $3.0 million from U.S. Bank, as modified by that certain loan modification agreement dated August 28, 2017. Approximately $2.4 million is due and owing U.S. Bank as of September 30, 2017 under the revolving line of credit and a term note issued to U.S. Bank. The maturity date of the line of credit is currently December 15, 2017, and the Company currently does not anticipate that such line of credit will be extended or renewed. On October 27, 2017, the Company received a notice of default from U.S. Bank related to the line of credit and term loan. As such, if the Company is unable to enter into a loan agreement with an alternative lender prior to December 15, 2017, or in the event that all amounts due U.S. Bank are accelerated, the Company’s financial condition will be negatively affected, and such affect will be material.

Filed Nov 14, 2017.
Source: SEC EDGAR, the filing index for accession 0001654954-17-010632. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
